Novo Nordisk Stock Decline

News

CEO of Novo Nordisk, maker of weight loss drug Wegovy

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.

· 3d · on MSN

Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market Challenges

· 4d · on MSN

Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.

4don MSN

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Zacks Investment Research on MSN4d

Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk ousts boss as Ozempic maker battles slump

Novo Nordisk has ousted chief executive Lars Fruergaard Jørgensen as the maker of pioneering obesity drug Ozempic battles a slump in profit growth, declining market share and a plunging stock price.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results